Top Page
Compumedics Limited
(Sydney:CMP)
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
Compumedics Limited Business Overview & Revenue Model
Compumedics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.04M | 51.04M | 49.72M | 42.41M | 37.76M | 35.74M |
| Gross Profit | 30.99M | 30.99M | 26.07M | 21.59M | 19.32M | 19.16M |
| EBITDA | 1.94M | 1.94M | 2.79M | -5.05M | 3.31M | 2.56M |
| Net Income | -1.27M | -1.27M | -338.00K | -6.12M | 1.36M | 998.00K |
Balance Sheet | ||||||
| Total Assets | 54.39M | 54.39M | 40.36M | 41.18M | 41.71M | 38.55M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.69M | 1.89M | 3.80M | 7.29M | 6.77M |
| Total Debt | 13.88M | 13.88M | 8.58M | 9.47M | 6.55M | 5.82M |
| Total Liabilities | 32.57M | 32.57M | 22.15M | 22.89M | 18.12M | 16.39M |
| Stockholders Equity | 21.82M | 21.82M | 18.21M | 18.29M | 23.59M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | 467.00K | 467.00K | -986.00K | -4.36M | 302.00K | -230.00K |
| Operating Cash Flow | 681.00K | 681.00K | 2.00M | 49.00K | 3.29M | 1.32M |
| Investing Cash Flow | -7.35M | -7.37M | -2.99M | -4.41M | -2.98M | -1.55M |
| Financing Cash Flow | 6.10M | 6.10M | -1.49M | -1.00M | 1.61M | -179.00K |
Compumedics Limited Technical Analysis
Compumedics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $172.36M | ― | -7.26% | ― | 21.65% | 81.40% | |
| ― | AU$64.39M | -48.55 | -6.35% | ― | 2.23% | -263.16% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $101.81M | ― | -74.00% | ― | 23.31% | -17.35% | |
| ― | AU$170.03M | -16.13 | -70.55% | ― | ― | -257.32% | |
| ― | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% | |
| ― | AU$14.14M | ― | -103.74% | ― | 14.84% | 39.64% |
Compumedics Limited Corporate Events
Compumedics Limited has issued 7,543,860 fully paid ordinary shares to Australian institutional investors at AU$0.285 per share. This issuance, which did not require disclosure under the Corporations Act, aligns with Compumedics’ compliance with relevant legislative provisions. The move is part of the company’s ongoing efforts to strengthen its financial position and expand its market reach.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a projected revenue of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neurological diagnostics across various regions, including Australia, Japan, China, and the USA, and continues to expand its presence in the global medical technology market.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has secured early FDA approval for its Somfit D product and raised $2.15 million to accelerate its commercialization in the US home sleep testing market. The company is entering a significant commercial expansion phase, with strategic growth pillars including scaling Somfit in the US, expanding OrionMEG globally, and leveraging SaaS-driven margin expansion. The funds will be used to fast-track production and support the growing demand for Somfit D and OrionMEG, positioning Compumedics for a structural valuation re-rating against peers.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has requested a trading halt on the Australian Securities Exchange, effective immediately, pending an announcement regarding a proposed capital raising. The halt is expected to last until the start of normal trading on October 15, 2025, unless an announcement is made earlier. This move indicates that Compumedics is preparing for a significant financial development, which could impact its market position and stakeholder interests.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited reported record sales orders of $63.4 million, marking a 22% increase, and revenue of $51 million, up 15% from the previous year. The company has achieved significant growth in its Somfit SaaS platform, securing a $10 million U.S. pipeline and forming strategic partnerships with major pharmaceutical companies. With FDA clearance for its products and expansion into new markets, Compumedics is positioned for continued growth in FY26, projecting revenues over $70 million.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has reaffirmed its commitment to high standards of corporate governance, emphasizing the importance of a strong relationship between the Board and senior management for the Group’s long-term success. The Board’s responsibilities include strategic guidance, financial oversight, and ensuring effective management processes, with a focus on enhancing shareholder and stakeholder interests.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has announced details regarding its upcoming Annual General Meeting, which will be held virtually and physically on October 30, 2025. Shareholders are encouraged to participate through an online platform, where they can watch, listen, and vote on various resolutions, including the election of a director and the adoption of a remuneration report. This meeting is significant for stakeholders as it provides an opportunity to influence key decisions and company governance.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has announced its Annual General Meeting (AGM) scheduled for October 30, 2025, which will be held as a hybrid event, allowing shareholders to participate both in-person and virtually via a Zoom webinar. The AGM will cover the company’s financial statements, the election of a director, and the adoption of the remuneration report. The meeting provides an opportunity for shareholders to engage with the company’s leadership and vote on key resolutions, reflecting Compumedics’ commitment to transparency and shareholder involvement.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has released its 2025 Annual Report, highlighting its strategic growth platforms and core products in the sleep and neuroscience sectors. The report outlines the company’s ongoing commitment to innovation and market expansion, which is expected to enhance its industry positioning and provide significant value to stakeholders.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a forecast of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neuro diagnostics in Australia and Japan, is the top supplier of sleep diagnostics devices in China, and ranks as the third supplier of TCD devices in Germany and neurological monitoring devices in the USA, enhancing its industry positioning and stakeholder confidence.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has appointed Christopher R. Barys, a seasoned MedTech executive, as a Non-Executive Director to enhance its U.S. growth and capital market strategy. This strategic move aims to leverage Barys’ extensive experience and networks to address the company’s valuation gap compared to global peers and accelerate the commercialization of its Somfit® and OrionMEG® products. The company reported a 22% year-on-year increase in sales orders and anticipates further growth with a projected revenue exceeding $70 million in FY26. The strengthened board will focus on strategic partnerships and investor relations to unlock Compumedics’ potential in the U.S. market.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has received FDA clearance for its new single-use home sleep testing device, Somfit®D, which significantly expands its addressable market in the U.S. The device complements the existing reusable Somfit® platform, allowing Compumedics to offer a comprehensive EEG-based solution for both single-use and reusable markets. This strategic move positions the company to capture a substantial share of the U.S. home sleep testing market, estimated at US$240 million annually, and supports its recurring revenue growth model. With an established U.S. salesforce and existing relationships with diagnostic facilities, Compumedics is poised for immediate commercialization and aims for significant market penetration by FY27.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has achieved record sales orders of $63.4 million and revenues of $51 million for FY25, with an EBITDA of $2.9 million. The company’s growth is driven by significant investments in its Somfit U.S. business and the MEG market, with a strong sales momentum in the U.S. and Asia. The company is strategically expanding its presence in the U.S. and Asia, with a focus on recurring revenue streams and innovative technologies. The launch of Somfit-D and expansion into the MEG market are expected to capture substantial market shares, positioning Compumedics for sustainable growth.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited reported a pivotal year in FY25, achieving record sales orders and revenue while advancing its growth agenda. The company saw a 22% increase in sales orders to $63.4 million and a 2% rise in revenue to $51.0 million, driven by strong performance in sleep diagnostics and SaaS, as well as renewed traction in the U.S. market. Despite a decrease in MEG revenue, underlying growth was approximately 13% when excluding this segment. The momentum in the U.S. and Asia positions Compumedics for a strong start to FY26.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
Compumedics Limited has announced significant sales of its Somfit devices to major pharmaceutical and clinical research organizations in the USA and Europe, with revenues nearing $2 million. These sales mark a strategic expansion into the pharmaceutical clinical trial market, showcasing Somfit’s advanced capabilities in sleep monitoring and its potential beyond traditional home sleep testing. The contracts underscore the growing importance of sleep data in drug trials and highlight Compumedics’ commitment to diversifying its global business and exploring new growth avenues.
Compumedics Limited has signed two new 4-year distribution agreements in China, valued at A$24.4 million, with long-term partners. These agreements, which include a minimum 10% annual growth commitment, aim to strengthen Compumedics’ presence in Northern and Eastern China, focusing on sleep diagnostics and neurology. This strategic move is part of Compumedics’ broader effort to diversify and stabilize its revenue streams geographically and across product lines, positioning the company for sustained growth in key international markets, particularly in Asia.